Drug Trial Radar · NCT05889182
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,328
Planned (sponsor's estimate)
Start
Jun 21, 2023
Primary completion
Aug 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 300 sites worldwide. Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Conditions
- Hidradenitis Suppurativa
Interventions
UpadacitinibDrug
Oral Tablets
PlaceboDrug
Oral Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 50Time frame: Baseline to Week 16
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Week 108
Locations
285 sites in 37 countries. Site status is shown where the registry gives one.
Cahaba Dermatology and Skin Health Center /ID# 254876
Birmingham, Alabama
Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272564
Fountain Hills, Arizona
Medical Dermatology Specialists /ID# 254226
Phoenix, Arizona
Mayo Clinic Hospital Scottsdale /ID# 254388
Scottsdale, Arizona
Banner University Medicine Dermatology /ID# 255853
Tucson, Arizona
Clinical Trials Institute - Northwest Arkansas /ID# 254924
Fayetteville, Arkansas
Burke Pharmaceutical Research /ID# 254238
Hot Springs, Arkansas
Arkansas Research Trials /ID# 254233
North Little Rock, Arkansas
Northwest Arkansas Clinical Trials Center /ID# 254311
Rogers, Arkansas
Private Practice - Dr. Tooraj Raoof /ID# 254374
Encino, California
Marvel Clinical Research /ID# 276228
Huntington Beach, California
Dermatology Research Associates /ID# 254846
Los Angeles, California
Norcal Clinical Research /ID# 274219
Rocklin, California
Integrative Skin Science and Research /ID# 254930
Sacramento, California
University of California Davis Health /ID# 254229
Sacramento, California
Medderm Associates /ID# 253800
San Diego, California
Clinical Trials Research Institute /ID# 254466
Thousand Oaks, California
UConn Health Main /ID# 254507
Farmington, Connecticut
Yale University School of Medicine /ID# 254586
New Haven, Connecticut
Skin Care Research Boca Raton /ID# 253814
Boca Raton, Florida
Apex Clinical Trials /ID# 255756
Brandon, Florida
Florida Academic Dermatology Center /ID# 254011
Coral Gables, Florida
Life Clinical Trials - Coral Springs /ID# 258613
Coral Springs, Florida
Dermatology Associates of the Palm Beaches /ID# 275950
Delray Beach, Florida
Skin Care Research - Hollywood /ID# 254508
Hollywood, Florida
Skin Care Research - Tampa /ID# 256440
Tampa, Florida
Advanced Clinical Research Institute - Tampa /ID# 253746
Tampa, Florida
Avita Clinical Research /ID# 254471
Tampa, Florida
Centricity Research - Columbus /ID# 255470
Columbus, Georgia
Treasure Valley Medical Research /ID# 255208
Boise, Idaho
Illinois Dermatology Institute - Chicago Loop Office /ID# 254372
Chicago, Illinois
Northwestern Medicine - Northwestern Memorial Hospital /ID# 254503
Chicago, Illinois
NorthShore University HealthSystem - Skokie /ID# 254389
Skokie, Illinois
Dawes Fretzin /ID# 254390
Indianapolis, Indiana
Options Research Group /ID# 254537
West Lafayette, Indiana
U.S. Dermatology Partners Leawood /ID# 255838
Leawood, Kansas
Equity Medical /ID# 271140
Bowling Green, Kentucky
Massachusetts General Hospital /ID# 261093
Boston, Massachusetts
Beth Israel Deaconess Medical Center /ID# 253811
Boston, Massachusetts
Beacon Clinical Research, LLC /ID# 254419
Quincy, Massachusetts
Showing 40 of 285 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.